Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium

<p>— Six abstracts have been accepted for presentation, including updated data on vepdegestrant alone and in combination with palbociclib (IBRANCE®) — NEW HAVEN, Conn. and NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced that updated clinical trial data for vepdegestrant (ARV-471) will be presented […]</p>
<p>The post <a href="https://forextv.com/top-news/arvinas-and-pfizer-announce-updated-vepdegestrant-arv-471-data-to-be-presented-at-the-2023-san-antonio-breast-cancer-symposium/">Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>